Lincoln Pharmaceuticals Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited (NSE) and BSE Limited regarding an upcoming board meeting.
The Board of Directors meeting is scheduled to be held on Thursday, August 13, 2026, at the company's Registered Office located at "Lincoln House", Science City Road, Sola, Ahmedabad-380 060, Gujarat, India.
The primary agenda for the meeting includes:
- Consideration and approval of unaudited financial results (both Standalone and Consolidated) for the quarter ended June 30, 2026 (Q1 FY27)
- Any other business with the permission of the Chairman
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the company's trading window for securities has been closed since July 01, 2026. The trading window will reopen after 48 hours from the time the financial results become generally available to the public.
This disclosure is made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.